Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications

Cancer

Volumn 101, Issue 6, 2004, Pages 1345-1356

  Chen, Gaoping ^a   Shukeir, Nicholas ^a   Potti, Anil ^b   Sircar, Kanishka ^a   Aprikian, Armen ^a   Goltzman, David ^a   Rabbani, Shafaat A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

catenin; Bone metastasis; Immunohistochemistry; Prostate carcinoma; Wnt 1

Indexed keywords

BETA CATENIN; TUMOR MARKER; WNT1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; AGED; ANDROGENS; BETA CATENIN; BONE NEOPLASMS; CYTOSKELETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; UP-REGULATION; WNT PROTEINS; WNT1 PROTEIN;

EID: 4444326415     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20518     Document Type: Article

References (56)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60-67.
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
3. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol. 2000;164:3-9.
4. Gumbiner BM. Carcinogenesis: a balance between beta-catenin and APC. Curr Biol. 1997;7:R443-R446.
5. Molenaar M, van de Wetering M, Oosterwegel M, et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 1996; 86:391-399.
6. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382:638-642.
7. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev. 1996;59:3-10.
8. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997;16:3797-3804.
9. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem. 1997;272:24735-24738.
10. Peifer M. Beta-catenin as oncogene: the smoking gun. Science. 1997;275:1752-1753.
11. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422-426.
12. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522-5527.
13. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512.
14. Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in Ape and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154:515-523.
15. Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA. 1999; 96:1603-1608.
16. Hlubek F, Jung A, Kotzor N, Kirchner T, Brabletz T. Expression of the invasion factor laminin gamma2 in colorectal carcinomas is regulated by beta-catenin. Cancer Res. 2001; 61:8089-8093.
17. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science. 1993;262: 1731-1734.
18. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-1790.
19. Tsujiuchi T, Tsutsumi M, Sasaki Y, Murata N, Konishi Y. Mutations of adenomatous polyposis coli and beta-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Res. 2000; 60:6611-6616.
20. Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999;18:5931-5942.
21. Bukholm IK, Nesland JM, Borresen-Dale AL. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol. 2000;190:15-19.
22. Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH. Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. Int J Cancer. 2001;95:108-113.
23. Utsunomiya T, Doki Y, Takemoto H, et al. Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology. 2001;61:226-233.
24. Kimura Y, Shiozaki H, Doki Y, et al. Cytoplasmic beta-catenin in esophageal cancers. Int J Cancer. 1999;84:174-178.
25. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8:450-456.
26. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer. 2001;95:194-197.
27. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59:1811-1815.
28. YokotaN, Nishizawa S, Ohta S, et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer. 2002;101:198-201.
29. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer. 2001;92:839-842.
30. Kallakury BV, Sheehan CE, Winn-Deen E, et al. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92:2786-2795.
31. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW, Schembri Wismayer D, George NJ. E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. BJU Int. 2002; 89:400-403.
32. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate. 2000;45:323-334.
33. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature. 1984;307:131-136.
34. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000;19:1002-1009.
35. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998.
36. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64.
37. Chen G, Burger MM. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer. 1999;84:95-100.
38. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1081;29:577-580.
39. Pizzi H, Gladu J, Carpio L, Miao D, Goltzman D, Rabbani SA. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology. 2003;144:858-867.
40. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986;17:64-71.
41. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol. 1997;158:12-22.
42. Gounari F, Signoretti S, Bronson R, et al. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 2002;21:4099-4107.
43. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14: 1837-1851.
44. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol. 1992;147:798-803.
45. Loda M, Fogt F, French FS, et al. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol. 1994;7:388-391.
46. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate. 1992;20:281-295.
47. Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate. 1998;35:63-70.
48. Hobisch A, Culig Z, Radmayr C, Bartsch G, Mocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 1995;55:3068-3072.
49. Hobisch A, Culig Z, Radmayr C, Bartsch G, Mocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. 1996;28:129-135.
50. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. T cell factor. Oncogene. 2002;21:8453-8469.
51. Yang F, Li X, Sharma M, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem. 2002;277:11336-11344.
52. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct beta catenin independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278: 30828-30834.
53. Liotta LA, Kohn E. Cancer invasion and metastases. JAMA. 1990;263:1123-1126.
54. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124: 995-1000.
55. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer. 2002;95: 2479-2486.
56. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer. 1999;81:1392-1397.